ContraFect Corporation (CFRX)

NASDAQ: CFRX · IEX Real-Time Price · USD
0.143
-0.007 (-4.67%)
At close: Dec 5, 2022 4:00 PM
0.148
+0.005 (3.50%)
After-hours: Dec 5, 2022 5:10 PM EST
-4.67%
Market Cap 5.90M
Revenue (ttm) n/a
Net Income (ttm) -59.71M
Shares Out 39.33M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 926,770
Open 0.149
Previous Close 0.15
Day's Range 0.141 - 0.157
52-Week Range 0.128 - 4.54
Beta 0.35
Analysts Buy
Price Target 3.74 (+2,515.4%)
Earnings Date Nov 21, 2022

About CFRX

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic... [Read more]

Industry Biotechnology
IPO Date Jul 29, 2014
CEO Roger Pomerantz
Employees 38
Stock Exchange NASDAQ
Ticker Symbol CFRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CFRX stock is "Buy." The 12-month stock price forecast is 3.74, which is an increase of 2,515.38% from the latest price.

Price Target
$3.74
(2,515.38% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), inc...

1 week ago - GlobeNewsWire

ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Continued execution to advance exebacase and CF-370 into new clinical studies Continued execution to advance exebacase and CF-370 into new clinical studies

3 weeks ago - GlobeNewsWire

ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and...

YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), in...

2 months ago - GlobeNewsWire

ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Pat...

YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), in...

2 months ago - GlobeNewsWire

ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Focused on advancement of lead programs, exebacase and CF-370, into new clinical studies Focused on advancement of lead programs, exebacase and CF-370, into new clinical studies

3 months ago - GlobeNewsWire

ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Impla...

YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), inc...

3 months ago - GlobeNewsWire

Why Is ContraFect (CFRX) Stock Down 80% Today?

A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging. The post Why Is ContraFect (CFRX) Stock Down 80% Today?

4 months ago - InvestorPlace

ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following In...

YONKERS, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins a...

4 months ago - GlobeNewsWire

Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect's Direct Lytic Agents (DLAs) to Address M...

YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

5 months ago - GlobeNewsWire

ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microb...

YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

5 months ago - GlobeNewsWire

ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic a...

6 months ago - GlobeNewsWire

ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update

Phase 3 DISRUPT study achieves enrollment of MRSA patients necessary for DSMB to conduct interim futility analysis Phase 3 DISRUPT study achieves enrollment of MRSA patients necessary for DSMB to conduc...

6 months ago - GlobeNewsWire

ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to...

Oral Session Demonstrates CF-370's Potent Activity in a Rabbit Pneumonia Model of an Extensively-Resistant Pseudomonas aeruginosa Infection Oral Session Demonstrates CF-370's Potent Activity in a Rabbit...

7 months ago - GlobeNewsWire

ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs)...

YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

7 months ago - GlobeNewsWire

ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update

Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated in H1 2022 Phase 3 DISRUPT study enrollment continues on course towards conducting interi...

8 months ago - GlobeNewsWire

ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference

YONKERS, N.Y., March 21, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

8 months ago - GlobeNewsWire

ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference

YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

9 months ago - GlobeNewsWire

ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Ser...

YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

10 months ago - GlobeNewsWire

Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRS...

Data from Single Pediatric Patient Highlights that FDA-Designated Breakthrough Therapy Exebacase May be a Beneficial Adjunctive Therapy for Severe MRSA Infections in Children Data from Single Pediatric ...

11 months ago - GlobeNewsWire

ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update

YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

1 year ago - GlobeNewsWire

ContraFect's New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections i...

Company's Direct Lytic Agents Lysin CF-370 and Amurin Peptide AM1 Show In Vitro Activity Against Prevalent Gram-Negative Pathogens Associated with Lung Infections in Patients with Cystic Fibrosis Compan...

1 year ago - GlobeNewsWire

ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients

YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

1 year ago - GlobeNewsWire

ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphy...

Data Being Presented Demonstrates Directly Positive Clinical Utility and Furthers the Understanding of Exebacase in Treating Staphylococcus aureus Bacteremia, Including Multidrug-Resistant MRSA Data Bei...

1 year ago - GlobeNewsWire

ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference

YONKERS, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

1 year ago - GlobeNewsWire

ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update

Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company's DLA portfolio

1 year ago - GlobeNewsWire